Perrigo Co PLC (PRGO): Cost of Revenue
$2.76B
Year ended 2025-12-31
$2.77B
Trailing 12 months to 2026-06-27
-2.7%
3-year compound annual growth
+1.2%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.76B | -2.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.83B | -4.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $2.98B | -0.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $3.00B | +10.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $2.72B | +5.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $2.59B | +6.4% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $2.44B | n/c | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $2.90B | -2.2% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $2.97B | -8.1% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $3.23B | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-27 and 2016-12-31. | |||
| 2015-06-27 | $2.58B | +4.9% | 2018-03-01, From 2014-06-29 |
| 2014-06-28 | $2.46B | n/c | 2017-05-22, From 2013-06-30 |
| 2013-06-29 | $2.26B | +8.8% | 2014-08-14, From 2012-07-01 |
| 2012-06-30 | $2.08B | n/a | 2014-08-14, From 2011-06-26 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $2.12B | +5.9% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $717.44M | +23.6% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $384.40M | +24.1% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $1.91B | +7.4% |
| Organon & Co. (OGN) | 2025-12-31 | $2.90B | +8.0% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $25.50M | n/a |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.67B | -1.9% |
Compare PRGO, ELAN, ALNY, BMRN side by side · Screen every company in Pharmaceutical Preparations ↗